Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases
Identifieur interne : 000837 ( Istex/Corpus ); précédent : 000836; suivant : 000838Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases
Auteurs : Kam Hon YoonSource :
- APLAR Journal of Rheumatology [ 0219-0494 ] ; 2004-05.
English descriptors
- Teeft :
- Adjuvantinduced arthritis, Adverse events, Antiphospholipid syndrome, Aplar journal, Arthritis, Arthritis rheum, Azathioprine, Azathioprine steroids, Chinese woman, Conventional therapy, Creatinine, Cutaneous manifestations, Cutaneous vasculitis, Cyclosporin, Disease conditions, Gastrointestinal symptoms, Good response, Immunosuppressive agents, Interstitial lung disease, Liver dysfunction, Liver function test, Lupus, Lupus erythematosus, Lupus nephritis, Malar rash, Mycophenolate, Mycophenolate steroids, National university hospital, Nephritis, Normal range, Partial responders, Patient example, Pediatric patients, Period november, Prednisolone, Psoriatic, Psoriatic arthritis, Renal biopsy, Renal transplantation, Resistant diseases, Rheum, Rheumatic diseases, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthritis patients, Rheumatology, Successful usage, Systemic lupus erythematosus, Tacrolimus, Topical tacrolimus.
Abstract
Aim: This study reports the first successful usage of tacrolimus in various resistant or relapsed rheumatic diseases in Asian patients Methods: This is an open prospective study of the efficacy of tacrolimus for patients with various relapsed/resistant rheumatic diseases who were intolerant of or failed conventional therapy. Patients were enrolled in the study from the period November 2001 to September 2002. Results: A total of 20 patients were included in the study. Their disease conditions were as follows: SLE with relapsed lupus nephritis (six patients); SLE with antiphospholipid syndrome (APS) (two patients); rheumatoid arthritis (five patients); psoriatic arthritis (three patients); scleroderma (two patients); anti–Jo−1 syndrome (two patients). Improvement in their conditions were noted in all but one patient who was intolerant to tacrolimus. Conclusions: Tacrolimus (FK506) is a new armamentarium that can be added to the choice of immunosuppressive agents for rheumatologists, especially for those patients with severe or resistant diseases.
Url:
DOI: 10.1111/j.1479-8077.2004.00064.x
Links to Exploration step
ISTEX:34E26F591602D0871E1EC31B9D3729D0F17020C1Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases</title><author><name sortKey="Yoon, Kam Hon" sort="Yoon, Kam Hon" uniqKey="Yoon K" first="Kam Hon" last="Yoon">Kam Hon Yoon</name><affiliation><mods:affiliation>Department of Medicine, National University Hospital, Singapore</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: mdcykh@singnet.com.sg</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:34E26F591602D0871E1EC31B9D3729D0F17020C1</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1111/j.1479-8077.2004.00064.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-BLJC5B5D-J/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000837</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000837</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases</title><author><name sortKey="Yoon, Kam Hon" sort="Yoon, Kam Hon" uniqKey="Yoon K" first="Kam Hon" last="Yoon">Kam Hon Yoon</name><affiliation><mods:affiliation>Department of Medicine, National University Hospital, Singapore</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: mdcykh@singnet.com.sg</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">APLAR Journal of Rheumatology</title><title level="j" type="alt">APLAR JOURNAL OF RHEUMATOLOGY</title><idno type="ISSN">0219-0494</idno><idno type="eISSN">1479-8077</idno><imprint><biblScope unit="vol">7</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="44">44</biblScope><biblScope unit="page" to="48">48</biblScope><biblScope unit="page-count">5</biblScope><publisher>Blackwell Science Pty</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2004-05">2004-05</date></imprint><idno type="ISSN">0219-0494</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0219-0494</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adjuvantinduced arthritis</term><term>Adverse events</term><term>Antiphospholipid syndrome</term><term>Aplar journal</term><term>Arthritis</term><term>Arthritis rheum</term><term>Azathioprine</term><term>Azathioprine steroids</term><term>Chinese woman</term><term>Conventional therapy</term><term>Creatinine</term><term>Cutaneous manifestations</term><term>Cutaneous vasculitis</term><term>Cyclosporin</term><term>Disease conditions</term><term>Gastrointestinal symptoms</term><term>Good response</term><term>Immunosuppressive agents</term><term>Interstitial lung disease</term><term>Liver dysfunction</term><term>Liver function test</term><term>Lupus</term><term>Lupus erythematosus</term><term>Lupus nephritis</term><term>Malar rash</term><term>Mycophenolate</term><term>Mycophenolate steroids</term><term>National university hospital</term><term>Nephritis</term><term>Normal range</term><term>Partial responders</term><term>Patient example</term><term>Pediatric patients</term><term>Period november</term><term>Prednisolone</term><term>Psoriatic</term><term>Psoriatic arthritis</term><term>Renal biopsy</term><term>Renal transplantation</term><term>Resistant diseases</term><term>Rheum</term><term>Rheumatic diseases</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid arthritis patients</term><term>Rheumatology</term><term>Successful usage</term><term>Systemic lupus erythematosus</term><term>Tacrolimus</term><term>Topical tacrolimus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Aim: This study reports the first successful usage of tacrolimus in various resistant or relapsed rheumatic diseases in Asian patients Methods: This is an open prospective study of the efficacy of tacrolimus for patients with various relapsed/resistant rheumatic diseases who were intolerant of or failed conventional therapy. Patients were enrolled in the study from the period November 2001 to September 2002. Results: A total of 20 patients were included in the study. Their disease conditions were as follows: SLE with relapsed lupus nephritis (six patients); SLE with antiphospholipid syndrome (APS) (two patients); rheumatoid arthritis (five patients); psoriatic arthritis (three patients); scleroderma (two patients); anti–Jo−1 syndrome (two patients). Improvement in their conditions were noted in all but one patient who was intolerant to tacrolimus. Conclusions: Tacrolimus (FK506) is a new armamentarium that can be added to the choice of immunosuppressive agents for rheumatologists, especially for those patients with severe or resistant diseases.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>tacrolimus</json:string><json:string>lupus</json:string><json:string>cyclosporin</json:string><json:string>nephritis</json:string><json:string>rheumatoid</json:string><json:string>lupus nephritis</json:string><json:string>prednisolone</json:string><json:string>creatinine</json:string><json:string>psoriatic</json:string><json:string>arthritis rheum</json:string><json:string>mycophenolate</json:string><json:string>azathioprine</json:string><json:string>rheumatoid arthritis</json:string><json:string>rheumatology</json:string><json:string>arthritis</json:string><json:string>psoriatic arthritis</json:string><json:string>malar rash</json:string><json:string>aplar journal</json:string><json:string>conventional therapy</json:string><json:string>rheum</json:string><json:string>rheumatic diseases</json:string><json:string>azathioprine steroids</json:string><json:string>lupus erythematosus</json:string><json:string>interstitial lung disease</json:string><json:string>pediatric patients</json:string><json:string>adverse events</json:string><json:string>successful usage</json:string><json:string>systemic lupus erythematosus</json:string><json:string>national university hospital</json:string><json:string>partial responders</json:string><json:string>cutaneous vasculitis</json:string><json:string>disease conditions</json:string><json:string>antiphospholipid syndrome</json:string><json:string>mycophenolate steroids</json:string><json:string>good response</json:string><json:string>renal biopsy</json:string><json:string>liver dysfunction</json:string><json:string>immunosuppressive agents</json:string><json:string>gastrointestinal symptoms</json:string><json:string>normal range</json:string><json:string>chinese woman</json:string><json:string>patient example</json:string><json:string>renal transplantation</json:string><json:string>topical tacrolimus</json:string><json:string>cutaneous manifestations</json:string><json:string>adjuvantinduced arthritis</json:string><json:string>liver function test</json:string><json:string>rheumatoid arthritis patients</json:string><json:string>period november</json:string><json:string>resistant diseases</json:string></teeft></keywords><author><json:item><name>Kam Hon Yoon</name><affiliations><json:string>Department of Medicine, National University Hospital, Singapore</json:string><json:string>E-mail: mdcykh@singnet.com.sg</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>lupus nephritis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>relapsed/resistant disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>tacrolimus</value></json:item></subject><articleId><json:string>APL064</json:string></articleId><arkIstex>ark:/67375/WNG-BLJC5B5D-J</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Aim: This study reports the first successful usage of tacrolimus in various resistant or relapsed rheumatic diseases in Asian patients Methods: This is an open prospective study of the efficacy of tacrolimus for patients with various relapsed/resistant rheumatic diseases who were intolerant of or failed conventional therapy. Patients were enrolled in the study from the period November 2001 to September 2002. Results: A total of 20 patients were included in the study. Their disease conditions were as follows: SLE with relapsed lupus nephritis (six patients); SLE with antiphospholipid syndrome (APS) (two patients); rheumatoid arthritis (five patients); psoriatic arthritis (three patients); scleroderma (two patients); anti–Jo−1 syndrome (two patients). Improvement in their conditions were noted in all but one patient who was intolerant to tacrolimus. Conclusions: Tacrolimus (FK506) is a new armamentarium that can be added to the choice of immunosuppressive agents for rheumatologists, especially for those patients with severe or resistant diseases.</abstract><qualityIndicators><score>6.64</score><pdfWordCount>2828</pdfWordCount><pdfCharCount>18642</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>5</pdfPageCount><pdfPageSize>595 x 779 pts</pdfPageSize><pdfWordsPerPage>566</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>151</abstractWordCount><abstractCharCount>1064</abstractCharCount><keywordCount>3</keywordCount></qualityIndicators><title>Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases</title><genre><json:string>article</json:string></genre><host><title>APLAR Journal of Rheumatology</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1479-8077</json:string></doi><issn><json:string>0219-0494</json:string></issn><eissn><json:string>1479-8077</json:string></eissn><publisherId><json:string>APL</json:string></publisherId><volume>7</volume><issue>1</issue><pages><first>44</first><last>48</last><total>5</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2000</json:string><json:string>2001</json:string><json:string>2002</json:string><json:string>2003</json:string><json:string>1984</json:string><json:string>2004</json:string></date><geogName></geogName><orgName><json:string>National University Hospital</json:string><json:string>YOON Department of Medicine, National University Hospital, Singapore Abstract Aim</json:string><json:string>Department of Medicine, National University Hospital, Singapore</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Asia Paci</json:string><json:string>K. H. Yoon</json:string><json:string>Asian</json:string></persName><placeName><json:string>Singapore</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Wilkes et al.</json:string><json:string>February 2003</json:string><json:string>April 2003</json:string><json:string>David Yocum et al.</json:string><json:string>June 2003</json:string><json:string>Joel Kremer et al.</json:string><json:string>Gremillion et al.</json:string><json:string>Duddridge et al.</json:string><json:string>Furst et al.</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-BLJC5B5D-J</json:string></ark><categories><wos></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - arthritis & rheumatology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Rheumatology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2004</publicationDate><copyrightDate>2004</copyrightDate><doi><json:string>10.1111/j.1479-8077.2004.00064.x</json:string></doi><id>34E26F591602D0871E1EC31B9D3729D0F17020C1</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-BLJC5B5D-J/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-BLJC5B5D-J/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-BLJC5B5D-J/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases</title><title level="a" type="short">Tacrolimus resistant/relapsed rheumatic diseases</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Science Pty</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2004-05"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases</title><title level="a" type="short">Tacrolimus resistant/relapsed rheumatic diseases</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">Kam Hon</forename><surname>Yoon</surname></persName><affiliation><orgName type="division">Department of Medicine</orgName><orgName type="institution">National University Hospital</orgName><address><addrLine>Singapore</addrLine><country key="SG" xml:lang="en">SINGAPORE</country></address></affiliation></author><idno type="istex">34E26F591602D0871E1EC31B9D3729D0F17020C1</idno><idno type="ark">ark:/67375/WNG-BLJC5B5D-J</idno><idno type="DOI">10.1111/j.1479-8077.2004.00064.x</idno><idno type="unit">APL064</idno><idno type="toTypesetVersion">file:APL.APL064.pdf</idno></analytic><monogr><title level="j" type="main">APLAR Journal of Rheumatology</title><title level="j" type="alt">APLAR JOURNAL OF RHEUMATOLOGY</title><idno type="pISSN">0219-0494</idno><idno type="eISSN">1479-8077</idno><idno type="book-DOI">10.1111/(ISSN)1479-8077</idno><idno type="book-part-DOI">10.1111/apl.2004.7.issue-1</idno><idno type="product">APL</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">7</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="44">44</biblScope><biblScope unit="page" to="48">48</biblScope><biblScope unit="page-count">5</biblScope><publisher>Blackwell Science Pty</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2004-05"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><p><hi rend="bold">Aim: </hi> This study reports the first successful usage of tacrolimus in various resistant or relapsed rheumatic diseases in Asian patients</p><p><hi rend="bold">Methods: </hi> This is an open prospective study of the efficacy of tacrolimus for patients with various relapsed/resistant rheumatic diseases who were intolerant of or failed conventional therapy. Patients were enrolled in the study from the period November 2001 to September 2002.</p><p><hi rend="bold">Results: </hi> A total of 20 patients were included in the study. Their disease conditions were as follows: SLE with relapsed lupus nephritis (six patients); SLE with antiphospholipid syndrome (APS) (two patients); rheumatoid arthritis (five patients); psoriatic arthritis (three patients); scleroderma (two patients); anti–Jo−1 syndrome (two patients). Improvement in their conditions were noted in all but one patient who was intolerant to tacrolimus.</p><p><hi rend="bold">Conclusions: </hi> Tacrolimus (FK506) is a new armamentarium that can be added to the choice of immunosuppressive agents for rheumatologists, especially for those patients with severe or resistant diseases.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">lupus nephritis</term><term xml:id="k2">relapsed/resistant disease</term><term xml:id="k3">tacrolimus</term></keywords><keywords rend="tocHeading1"><term>ORIGINAL ARTICLES</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-BLJC5B5D-J/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Science Pty</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1479-8077</doi><issn type="print">0219-0494</issn><issn type="electronic">1479-8077</issn><idGroup><id type="product" value="APL"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="APLAR JOURNAL OF RHEUMATOLOGY">APLAR Journal of Rheumatology</title></titleGroup></publicationMeta><publicationMeta level="part" position="05001"><doi origin="wiley">10.1111/apl.2004.7.issue-1</doi><numberingGroup><numbering type="journalVolume" number="7">7</numbering><numbering type="journalIssue" number="1">1</numbering></numberingGroup><coverDate startDate="2004-05">May 2004</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="9" status="forIssue"><doi origin="wiley">10.1111/j.1479-8077.2004.00064.x</doi><idGroup><id type="unit" value="APL064"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="tocHeading1">ORIGINAL ARTICLES</title></titleGroup><eventGroup><event type="firstOnline" date="2004-04-05"></event><event type="publishedOnlineFinalForm" date="2004-04-05"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-05"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-04"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="44">44</numbering><numbering type="pageLast" number="48">48</numbering></numberingGroup><correspondenceTo><i>Correspondance</i>: KH Yoon, Arthritis and Rheumatism Specialist Medical Centre, Blk 102 Towner Road, #01–258 Singapore 322102. Email: <email>mdcykh@singnet.com.sg</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:APL.APL064.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="23"></count><count type="wordTotal" number="2636"></count></countGroup><titleGroup><title type="main">Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases</title><title type="shortAuthors">K. H. Yoon</title><title type="short">Tacrolimus resistant/relapsed rheumatic diseases</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1" corresponding="yes"><personName><givenNames>Kam Hon</givenNames><familyName>Yoon</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="SG"><unparsedAffiliation>Department of Medicine, National University Hospital, Singapore</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">lupus nephritis</keyword><keyword xml:id="k2">relapsed/resistant disease</keyword><keyword xml:id="k3">tacrolimus</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p><b>Aim: </b> This study reports the first successful usage of tacrolimus in various resistant or relapsed rheumatic diseases in Asian patients</p><p><b>Methods: </b> This is an open prospective study of the efficacy of tacrolimus for patients with various relapsed/resistant rheumatic diseases who were intolerant of or failed conventional therapy. Patients were enrolled in the study from the period November 2001 to September 2002.</p><p><b>Results: </b> A total of 20 patients were included in the study. Their disease conditions were as follows: SLE with relapsed lupus nephritis (six patients); SLE with antiphospholipid syndrome (APS) (two patients); rheumatoid arthritis (five patients); psoriatic arthritis (three patients); scleroderma (two patients); anti–Jo−1 syndrome (two patients). Improvement in their conditions were noted in all but one patient who was intolerant to tacrolimus.</p><p><b>Conclusions: </b> Tacrolimus (FK506) is a new armamentarium that can be added to the choice of immunosuppressive agents for rheumatologists, especially for those patients with severe or resistant diseases.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Tacrolimus resistant/relapsed rheumatic diseases</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases</title></titleInfo><name type="personal"><namePart type="given">Kam Hon</namePart><namePart type="family">Yoon</namePart><affiliation>Department of Medicine, National University Hospital, Singapore</affiliation><affiliation>E-mail: mdcykh@singnet.com.sg</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Blackwell Science Pty</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2004-05</dateIssued><copyrightDate encoding="w3cdtf">2004</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">0</extent><extent unit="tables">2</extent><extent unit="formulas">0</extent><extent unit="references">23</extent><extent unit="words">2636</extent></physicalDescription><abstract lang="en">Aim: This study reports the first successful usage of tacrolimus in various resistant or relapsed rheumatic diseases in Asian patients Methods: This is an open prospective study of the efficacy of tacrolimus for patients with various relapsed/resistant rheumatic diseases who were intolerant of or failed conventional therapy. Patients were enrolled in the study from the period November 2001 to September 2002. Results: A total of 20 patients were included in the study. Their disease conditions were as follows: SLE with relapsed lupus nephritis (six patients); SLE with antiphospholipid syndrome (APS) (two patients); rheumatoid arthritis (five patients); psoriatic arthritis (three patients); scleroderma (two patients); anti–Jo−1 syndrome (two patients). Improvement in their conditions were noted in all but one patient who was intolerant to tacrolimus. Conclusions: Tacrolimus (FK506) is a new armamentarium that can be added to the choice of immunosuppressive agents for rheumatologists, especially for those patients with severe or resistant diseases.</abstract><subject lang="en"><genre>keywords</genre><topic>lupus nephritis</topic><topic>relapsed/resistant disease</topic><topic>tacrolimus</topic></subject><relatedItem type="host"><titleInfo><title>APLAR Journal of Rheumatology</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0219-0494</identifier><identifier type="eISSN">1479-8077</identifier><identifier type="DOI">10.1111/(ISSN)1479-8077</identifier><identifier type="PublisherID">APL</identifier><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>44</start><end>48</end><total>5</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Tacrolimus</title></titleInfo><name type="personal"><namePart type="given">GB</namePart><namePart type="family">Klintmalm</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>book-chapter</genre><relatedItem type="host"><titleInfo><title>Transplanatation</title></titleInfo><originInfo><publisher>Blackwell Science</publisher></originInfo><part><date>1999</date><extent unit="pages"><start>127</start><end>46</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>FK506 attenuates developing and established joint inflammation and suppresses interleukin 6 and nitric oxide expression in bacteria cell wall induced polyarthritis</title></titleInfo><name type="personal"><namePart type="given">JW</namePart><namePart type="family">Fuseler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Hearth‐holmes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MB</namePart><namePart type="family">Grisham</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fuseler JW, Hearth‐holmes M, Grisham MB et al. (2000) FK506 attenuates developing and established joint inflammation and suppresses interleukin 6 and nitric oxide expression in bacteria cell wall induced polyarthritis. J Rheumatol 27, 190–9.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>190</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>190</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Fk506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvant‐induced arthritis</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Sakuma</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Nishigaki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Magari</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Ogawa</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Miyata</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Ohkubo</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sakuma S, Nishigaki F, Magari K, Ogawa T, Miyata S, Ohkubo Y (2001) Fk506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvant‐induced arthritis. Inflamm Res 50, 509–14.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>509</start><end>14</end></extent></part><relatedItem type="host"><titleInfo><title>Inflamm Res</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>509</start><end>14</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Effects of FK506 and other immunosuppressive anti‐rheumatic agents on T‐cell activation mediated IL‐6 and IgM production in‐vitro</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Sakuma</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Kato</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Nishigaki</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sakuma S, Kato Y, Nishigaki F et al. (2001) Effects of FK506 and other immunosuppressive anti‐rheumatic agents on T‐cell activation mediated IL‐6 and IgM production in‐vitro. Int Immunopharmacol 1, 749–57.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>1</number></detail><extent unit="pages"><start>749</start><end>57</end></extent></part><relatedItem type="host"><titleInfo><title>Int Immunopharmacol</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>1</number></detail><extent unit="pages"><start>749</start><end>57</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>FK506 augments glucocorticoid‐mediated cyclooxygenase‐regulation in human rheumatoid synovial fibroblasts</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">Migita</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Tanaka</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Okamoto</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Migita K, Tanaka H, Okamoto K et al. (2000) FK506 augments glucocorticoid‐mediated cyclooxygenase‐regulation in human rheumatoid synovial fibroblasts. Laboratory Invest 80, 135–41.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>135</start><end>41</end></extent></part><relatedItem type="host"><titleInfo><title>Laboratory Invest</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>135</start><end>41</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Effect of FK506, a novel immunosuppressive drug on murine systemic lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">Takabayashi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Koike</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Kurasawa</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Takabayashi K, Koike T, Kurasawa K et al. (1989) Effect of FK506, a novel immunosuppressive drug on murine systemic lupus erythematosus. Clin Immunol Immunopathol 51, 110–7.</note><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>110</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Immunol Immunopathol</title></titleInfo><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>110</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ‐Ipr/Ipr mice</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Entani</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Izumino</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Iida</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Entani C, Izumino K, Iida H et al. (1993) Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ‐Ipr/Ipr mice. Nephron 64, 471–5.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>471</start><end>5</end></extent></part><relatedItem type="host"><titleInfo><title>Nephron</title></titleInfo><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>471</start><end>5</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant‐induced arthritis</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">Magari</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Miyata</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Nishigaki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Ohkubo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Mutoh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Goto</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S, Goto T (2003) Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant‐induced arthritis. J Rheumatol 30, 2193–200.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>2193</start><end>200</end></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>2193</start><end>200</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Tacrolimus</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Sharpiro</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>book-chapter</genre><relatedItem type="host"><titleInfo><title>Current and future immunosuppressive therapies following transplantation</title></titleInfo><originInfo><publisher>Luwer Academic Publishers</publisher></originInfo><part><date>2001</date><extent unit="pages"><start>123</start><end>37</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Cyclosporine and tacrolimus‐associated thrombotic microangiopathy</title></titleInfo><name type="personal"><namePart type="given">PT</namePart><namePart type="family">Pham</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Peng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AH</namePart><namePart type="family">Wilkinson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pham PT, Peng A, Wilkinson AH (2000) Cyclosporine and tacrolimus‐associated thrombotic microangiopathy. Am J Kidney Dis 36, 844–50.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>844</start><end>50</end></extent></part><relatedItem type="host"><titleInfo><title>Am J Kidney Dis</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>844</start><end>50</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis: initial experience in 12 patients</title></titleInfo><name type="personal"><namePart type="given">RB</namePart><namePart type="family">Gremillion</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JO</namePart><namePart type="family">Posever Manek</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">West</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JP</namePart><namePart type="family">Van Volen‐Hoven</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gremillion RB, Posever Manek JO, West N, Van Volen‐Hoven JP (1999) Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis: initial experience in 12 patients. J Rheumatol 26, 2332–26.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>2332</start><end>26</end></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>2332</start><end>26</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate</title></titleInfo><name type="personal"><namePart type="given">DE</namePart><namePart type="family">Furst</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Saag</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MR</namePart><namePart type="family">Fleischmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Furst DE, Saag K, Fleischmann MR et al. (2002) Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate. Arthritis Rheum 46, 2020–8.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>2020</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>2020</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Combination treatment with tacrolimus (Prograf; FK506) and methotrexate in rheumatoid arthritis patients who are partial responders to methotrexate</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Kremer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Habros</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Kolba</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kremer J, Habros J, Kolba K et al. (2002) Combination treatment with tacrolimus (Prograf; FK506) and methotrexate in rheumatoid arthritis patients who are partial responders to methotrexate. Arthritis Rheum 46, S1378.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>S1378</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>S1378</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>Efficacy and safety of tacrolimus (Prograf; FK506) in the treatment of rheumatoid arthritis (RA) in patients who have failed one or more DMARDs</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Yocum</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Furst</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Kaine</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yocum D, Furst D, Kaine J et al. (2002) Efficacy and safety of tacrolimus (Prograf; FK506) in the treatment of rheumatoid arthritis (RA) in patients who have failed one or more DMARDs. Arthritis Rheum 46, S1381.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>S1381</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>S1381</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>Long term safety of tacrolimus (Prograf; FK506) in the treatment of rheumatoid arthritis (RA)</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Yocum</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Furst</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Bensen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yocum D, Furst D, Bensen W et al. (2002) Long term safety of tacrolimus (Prograf; FK506) in the treatment of rheumatoid arthritis (RA). Arthritis Rheum 46, S1444.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>S1444</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>S1444</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Duddridge</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RJ</namePart><namePart type="family">Powell</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Duddridge M, Powell RJ (1997) Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 56, 690–2.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>690</start><end>2</end></extent></part><relatedItem type="host"><titleInfo><title>Ann Rheum Dis</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>690</start><end>2</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>Teatment of pediatric patients with severe systemic lupus erythematosus with tacrolimus</title></titleInfo><name type="personal"><namePart type="given">SC</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Kimura</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Lieberman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Ebner‐Lyons</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Li SC, Kimura Y, Lieberman K, Ebner‐Lyons L (2003) Teatment of pediatric patients with severe systemic lupus erythematosus with tacrolimus. Arthritis Rheum 48, S1287.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>S1287</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>S1287</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Treatment of antisynthetase associated interstitial lung disease with tacrolimus in patients with idiopathic inflammatory myopathy</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Wilkes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Sereika</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Fertig</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Lucas</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Perez</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Oddis</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wilkes M, Sereika S, Fertig N, Lucas M, Perez A, Oddis C (2003) Treatment of antisynthetase associated interstitial lung disease with tacrolimus in patients with idiopathic inflammatory myopathy. Arthritis Rheum 48, S1081.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>S1081</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>S1081</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>Tacrolimus (FK506) – a new therapeutic agent for severe recalcitrant psoariasis</title></titleInfo><name type="personal"><namePart type="given">BV</namePart><namePart type="family">Jegasothy</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CD</namePart><namePart type="family">Ackerman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Todo</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jegasothy BV, Ackerman CD, Todo S et al. (1992) Tacrolimus (FK506) – a new therapeutic agent for severe recalcitrant psoariasis. Arch Dermatol 128, 781–5.</note><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>128</number></detail><extent unit="pages"><start>781</start><end>5</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>128</number></detail><extent unit="pages"><start>781</start><end>5</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>Tacrolimus for the treatment of gout in renal transplantation: case reports and review of literature</title></titleInfo><name type="personal"><namePart type="given">HL</namePart><namePart type="family">Pilmore</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Faire</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Ditter</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pilmore HL, Faire B, Ditter I (2001) Tacrolimus for the treatment of gout in renal transplantation: case reports and review of literature. Transplantation 72, 1073–5.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><extent unit="pages"><start>1073</start><end>5</end></extent></part><relatedItem type="host"><titleInfo><title>Transplantation</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><extent unit="pages"><start>1073</start><end>5</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>Efficacy of tacrolimus for treating the malar rash of systemic lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">T</namePart><namePart type="family">Kanekura</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Yoshii</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Terasaki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Miyoshi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Kanzaki</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kanekura T, Yoshii N, Terasaki K, Miyoshi H, Kanzaki T (2003) Efficacy of tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol 148, 353–6.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>148</number></detail><extent unit="pages"><start>353</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>148</number></detail><extent unit="pages"><start>353</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">SL</namePart><namePart type="family">Walker</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Kirby</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RJ</namePart><namePart type="family">Chalmers</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Walker SL, Kirby B, Chalmers RJ (2002) The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br J Dermatol 147, 405–6.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>147</number></detail><extent unit="pages"><start>405</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>147</number></detail><extent unit="pages"><start>405</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit23"><titleInfo><title>Efficacy of tacrolimus ointment for the treatment of cutaneous manifestations of juvenile dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">AL</namePart><namePart type="family">Nezondet‐Chetaille</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PA</namePart><namePart type="family">Nigrovic</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AL</namePart><namePart type="family">Woodward</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nezondet‐Chetaille AL, Nigrovic PA, Woodward AL et al. (2002) Efficacy of tacrolimus ointment for the treatment of cutaneous manifestations of juvenile dermatomyositis. Arthritis Rheum 46, S 768.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>S</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>S</start></extent></part></relatedItem></relatedItem><identifier type="istex">34E26F591602D0871E1EC31B9D3729D0F17020C1</identifier><identifier type="ark">ark:/67375/WNG-BLJC5B5D-J</identifier><identifier type="DOI">10.1111/j.1479-8077.2004.00064.x</identifier><identifier type="ArticleID">APL064</identifier><accessCondition type="use and reproduction" contentType="copyright">© Wiley. All rights reserved.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-13</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-BLJC5B5D-J/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000837 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000837 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:34E26F591602D0871E1EC31B9D3729D0F17020C1
|texte= Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases
}}
| This area was generated with Dilib version V0.6.33. |  |